Molecular Partners AG
MP0533
acute myeloid leukemia
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews MP0533 for acute myeloid leukemia around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 12h ago
“The Company is actively engaging with key opinion leaders and regulators to shape the next phase of development, and anticipates updating the clinical plan for MP0533 in H1 2026.”